Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal Cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 10, 2006, Pages

  Hochster, Howard S ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; ENDOTHELIAL CELL GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53;

AGE DISTRIBUTION; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; DEHYDRATION; DIARRHEA; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; STANDARDIZATION; TREATMENT OUTCOME; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 33750303524     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.005     Document Type: Article

References (20)

1. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
2. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
3. Hedrick E.E., Hurwitz H., Sarkar S., et al. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 22 (2004) 249s (abstr 3517)
4. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 16 (2005) 3706-3712
5. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
6. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
7. Fyfe G.A., Hurwitz I., Fehrenbacher T., et al. Bevacizumab plus irinotecan/5-FU/leucovorin for the treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol 22 (2004) 274 (abstr 3617)
8. Werther K., Christensen I.J., Brunner N., et al. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 26 (2000) 657-662
9. Nakayama Y., Sako T., Shibao K., et al. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 22 (2002) 2437-2442
10. Holden S.N., Ryan E., Kearns A., et al. Benefit from bevacizumab is independent of pretreatment plasma vascular endothelial growth factor-A in patients with metastatic colorectal cancer. J Clin Oncol 23 suppl (2005) 259s (abstr 3555)
11. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
12. Ince W.L., Jubb A.M., Holden S.N., et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97 (2005) 981-989
13. Hochster H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Final analysis of the TREE study. J Clin Oncol 24 suppl (2006) (abstr 3510)
14. Bendell J., Fernando N., Morse M., et al. A phase II study of oxaliplatin, capecitabine, and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 24 suppl (2006) 156s (abstr 3541)
15. Kopetz S., Eng C., Adinin R.B., et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). J Clin Oncol 24 suppl (2006) 165s (abstr 3579)
16. Grothey A., Hedrick E.E., Mass R.D., et al. Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107. J Clin Oncol 24 suppl (2006) 165s (abstr 3516)
17. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
18. Hecht J.R., Trarbach T., Jaeger E., et al. A randomized, double-blind, placebo-controlled phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222-584 or placebo (CONFIRM-1). J Clin Oncol 23 suppl (2005) 2s (abstr 3)
19. Koehne C., Bajetta E., Lin E., et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo (CONFIRM 2). J Clin Oncol 24 suppl (2006) 148s (abstr 3508)
20. Major P., Trarbach T., and Lenz H.-J. Meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients with metastatic colorectal cancer receiving FOLFOX4 and PTK/ZK to determine clinical benefit using progression-free survival in high LDH patients. J Clin Oncol 24 suppl (2006) 153s (abstr 3529)